Daiichi Sankyo

SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance
SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance
EP Vantage
breast cancer
AstraZeneca
Daiichi Sankyo
SABCS
trastuzumab deruxtecan
Flag link:
Seattle Genetics Claims Arbitration Rights in Daiichi Sankyo ADC Dispute
Seattle Genetics Claims Arbitration Rights in Daiichi Sankyo ADC Dispute
BioSpace
Seattle Genetics
Daiichi Sankyo
antibody-drug conjugate
Flag link:
Eyeing second Japanese approval, Daiichi and Exelixis announce positive pivotal for kidney drug
Eyeing second Japanese approval, Daiichi and Exelixis announce positive pivotal for kidney drug
Endpoints
Daiichi Sankyo
Exelixis
clinical trials
diabetic nephropathy
Minnebro
Flag link:
Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalates
Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalates
Pharmaforum
Daiichi Sankyo
Seattle Genetics
breast cancer
AstraZeneca
trastuzumab deruxtecan
Herceptin
Flag link:
Daiichi sues Seattle Genetics over tech used in high-profile ADC
Daiichi sues Seattle Genetics over tech used in high-profile ADC
Fierce Biotech
Daiichi Sankyo
Seattle Genetics
antibody-drug conjugate
AstraZeneca
DS-8201
Flag link:
Daiichi Sankyo pulls out of U.S. pain market amid oncology pivot, opioid scrutiny
Daiichi Sankyo pulls out of U.S. pain market amid oncology pivot, opioid scrutiny
Fierce Pharma
Daiichi Sankyo
oncology
painkillers
opioids
opioid crisis
Flag link:
Daiichi Sankyo initiates clinical trial of DS-7300 in collaboration with Sarah Cannon Research Institute
Daiichi Sankyo initiates clinical trial of DS-7300 in collaboration with Sarah Cannon Research Institute
Pharmaceutical Business Review
Daiichi Sankyo
Sarah Cannon Research Institute
antibody-drug conjugate
DS-7300
clinical trials
solid tumors
Flag link:
Recent Job Cuts in the Biopharma Industry
Recent Job Cuts in the Biopharma Industry
BioSpace
Tocagen
Sanofi
Amneal
Daiichi Sankyo
Integra Life Sciences
Aclaris
Bayer
Novartis
Illumina
Merck
Roche Molecular Systems
Prometheus Labs
layoffs
Flag link:
Astellas maintains lead over Daiichi Sankyo with CHMP okay for Xospata
Astellas maintains lead over Daiichi Sankyo with CHMP okay for Xospata
Pharmaforum
Astellas
AML
Xospata
Europe
Daiichi Sankyo
Flag link:
Astellas' AML drug wins over CHMP — strengthening lead on Daiichi Sankyo
Astellas' AML drug wins over CHMP — strengthening lead on Daiichi Sankyo
Endpoints
Astellas
FDA
gilteritinib
Europe
AML
Daiichi Sankyo
Flag link:
Daiichi Sankyo to cut 69 opioid sales jobs
Daiichi Sankyo to cut 69 opioid sales jobs
Beckers Hospital Review
Daiichi Sankyo
opioids
layoffs
drug reps
Flag link:
Daiichi Sankyo scores landmark FDA OK for rare tumor drug — albeit with restrictions
Daiichi Sankyo scores landmark FDA OK for rare tumor drug — albeit with restrictions
Endpoints
Daiichi Sankyo
FDA
pexidartinib
Turalio
tenosynovial giant cell tumors
Flag link:
FDA declines to approve Daiichi Sankyo's blood cancer treatment
FDA declines to approve Daiichi Sankyo's blood cancer treatment
Reuters
Daiichi Sankyo
FDA
quizartinib
acute myeloid leukemia
Flag link:
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
Motley Fool
Vertex Pharmaceuticals
VX-445
tezacaftor/ivacaftor
AbbVie
upadacatinib
Daiichi Sankyo
trastuzumab deruxtecan
Celgene
liso-cel
Novartis
LY3298176
Flag link:
Daiichi Sankyo Denies Report That It's Selling Over-the-Counter Drug Unit
Daiichi Sankyo Denies Report That It's Selling Over-the-Counter Drug Unit
BioSpace
Daiichi Sankyo
OTC
Flag link:
Daiichi Sankyo in talks over OTC unit sale – reports
Daiichi Sankyo in talks over OTC unit sale – reports
Pharmaforum
Daiichi Sankyo
M&A
OTC
Flag link:
Daiichi Sankyo comes up way short of promised avian flu vaccine production
Daiichi Sankyo comes up way short of promised avian flu vaccine production
Fierce Pharma
Daiichi Sankyo
vaccines
Japan
avian flu
drug shortages
Flag link:
Daiichi Sankyo Takes Two Products to FDA Advisory Panel; Gets One Yes, One No
Daiichi Sankyo Takes Two Products to FDA Advisory Panel; Gets One Yes, One No
BioSpace
Daiichi Sankyo
FDA
quizartinib
acute myeloid leukemia
pexidartinib
TGCT
Flag link:
FDA questions credibility of Daiichi data ahead of AdComm
FDA questions credibility of Daiichi data ahead of AdComm
Fierce Biotech
FDA
Daiichi Sankyo
quizartinib
acute myeloid leukemia
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
Yahoo/Benzinga
biotech
Achillion
Sesen Bio
The Medicines Company
Amgen
Daiichi Sankyo
earnings
Flag link:

Pages